Literature DB >> 8482854

Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin.

A Vashishtha1, V A Fischetti.   

Abstract

Vaccines based on a highly conserved cell surface exposed C-repeat region of the group A streptococcal M protein molecule have been found to induce protection against mucosal challenge by homologous and heterologous streptococcal serotypes. Rabbit hyperimmune antisera were produced to four partially overlapping peptides of the C-repeat region of M6 protein. These were examined by both direct and competitive ELISA and by Western blotting for their reactivity against mammalian coiled coil proteins such as laminin, myosin, light meromyosin, heavy meromyosin, and cardiac tropomyosin, and to the denatured forms of some of these molecules. All sera reacted strongly with the recombinant M6 protein molecule. In addition, antibodies to three of the peptides displayed generally low levels of cross-reactivity with at least one of the mammalian proteins, whereas antibodies to one peptide did not cross-react with any of the proteins tested. The observed reactivity was found to be directed predominantly against denatured forms of the mammalian molecules. For instance, the cleaved forms of myosin bound better to the cross-reactive antibodies than the intact molecule. Furthermore, heat-denatured heavy meromyosin competed severalfold better in competitive ELISA than the non-heat-denatured "native" form. Our results demonstrate that M protein peptides corresponding to epitopes shared among rheumatic fever-associated strains of streptococci can lead to the production of low levels of antibodies reactive with mammalian coiled coil molecules. These antibodies are directed against the denatured forms of these molecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482854

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.

Authors:  E R Brandt; T Teh; W A Relf; R I Hobb; M F Good
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 2.  Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Authors:  Martin H Holtmann; Peter R Galle
Journal:  Langenbecks Arch Surg       Date:  2004-02-04       Impact factor: 3.445

Review 3.  Prevention and treatment of rheumatic heart disease in the developing world.

Authors:  Andrew C Steer; Jonathan R Carapetis
Journal:  Nat Rev Cardiol       Date:  2009-09-15       Impact factor: 32.419

4.  Immunological relationship between the class I epitope of streptococcal M protein and myosin.

Authors:  A Quinn; K Ward; V A Fischetti; M Hemric; M W Cunningham
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Streptococcus pyogenes genes that promote pharyngitis in primates.

Authors:  Luchang Zhu; Randall J Olsen; Stephen B Beres; Matthew Ojeda Saavedra; Samantha L Kubiak; Concepcion C Cantu; Leslie Jenkins; Andrew S Waller; Zhizeng Sun; Timothy Palzkill; Adeline R Porter; Frank R DeLeo; James M Musser
Journal:  JCI Insight       Date:  2020-06-04

6.  Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein.

Authors:  M W Cunningham; S M Antone; M Smart; R Liu; S Kosanke
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

7.  Reactivity of rheumatic fever and scarlet fever patients' sera with group A streptococcal M protein, cardiac myosin, and cardiac tropomyosin: a retrospective study.

Authors:  K F Jones; S S Whitehead; M W Cunningham; V A Fischetti
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

8.  Vaccine strategies to prevent rheumatic fever.

Authors:  E R Brandt; M F Good
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 9.  Cutting edge issues in rheumatic fever.

Authors:  Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

10.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.